When Natasha Allard's close friend Dave was diagnosed with stage 4 testicular cancer at age 26, the University at Buffalo postdoctoral associate started paying more attention to how cancer was upending the lives of young ...
Oct 25, 2026
0
13
An investigational vaccine helped the immune system recognize and respond to mutations that drive most pancreatic cancers, according to results from a randomized phase 2 clinical trial led by Mayo Clinic researchers. The ...
Oct 24, 2026
0
109
Prostate cancer is the most common cancer in men—in 2013, it affected more than 1 million men across the world. The cancer does not behave the same way in every patient, and doctors have long faced a difficult balancing act ...
Oct 23, 2026
0
349
Pancreatic cancer is one of the most aggressive and difficult-to-treat cancers. One reason for its resistance to therapy is the dense tissue surrounding the tumor that acts as a protective barrier and suppresses the immune ...
Oct 23, 2026
0
110
New research indicates that commonly used measures of kidney function underestimate the prevalence of chronic kidney disease (CKD) in patients with cancer. The findings will be presented at ASN Kidney Week 2026, Oct. 22–25.
Oct 23, 2026
0
9
In a world-first international trial, adding intismeran, a type of personalized therapeutic cancer vaccine made from each patient's own tumor, to pembrolizumab immunotherapy after surgery for high-risk melanoma reduced the ...
Oct 23, 2026
0
28
About 10% of cancers are linked to an inherited genetic variant, but as few as one in 15 cancer patients eligible for genetic testing complete it.
Oct 23, 2026
0
7
Research published today identifies potential new ways to treat the most common type of colorectal cancer in Ireland. The study, conducted by an international research team led by RCSI University of Medicine and Health Sciences ...
Oct 23, 2026
0
9
Early results of the first clinical trial to evaluate the drug invikafusp alfa (invika) in humans indicate that the treatment may be capable of managing cancers that have rebuffed most other interventions, including standard ...
Oct 23, 2026
0
267
A new analysis of a phase 3 clinical trial found that the targeted drug daraxonrasib improved survival compared with standard chemotherapy across multiple groups of patients with advanced pancreatic cancer, including those ...
Oct 23, 2026
0
7
